• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ATRS

ATRS

Antares Pharma, Inc.

NASDAQHealthcareMedical - Instruments & SuppliesUS

USD5.59

+0.01 (+0.18%)

Company Profile

CEO

Robert Apple

IPO Date

1996-10-03

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.58

Prev. Close

$5.58

Day Low

$5.58

Day High

$5.59

52W Low

$3.11

52W High

$5.60

Volume

1.76M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

28.6%

Avg Negative

2.7%

Avg Neutral

68.7%

News Feed

Antares Pharma Reports Second Quarter 2021 Financial and Operating Results

GlobeNewsWire·8/5/2021·↑ positive

Antares Pharma to Report Second Quarter 2021 Financial and Operating Results

GlobeNewsWire·7/28/2021·↓ negative

Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue

GlobeNewsWire
·7/22/2021
·↑ positive

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

GlobeNewsWire·6/28/2021·↑ positive

Antares Pharma to Present at the Raymond James Human Health Innovations Conference

GlobeNewsWire·6/15/2021·↑ positive

Antares Pharma (ATRS) Meets Q1 Earnings Estimates

Zacks Investment Research·5/6/2021·↑ positive

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

GlobeNewsWire·5/6/2021·↓ negative

Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting

GlobeNewsWire·5/3/2021·↑ positive

Antares Pharma to Report First Quarter 2021 Financial and Operating Results

GlobeNewsWire·4/27/2021·↓ negative

Antares Pharma - Why It's A $4 Stock (And Might Remain So)

Seeking Alpha·4/26/2021·↑ positive